Science and Research

Bronchodilator Response in Post-COVID-19 Patients Undergoing Pulmonary Rehabilitation

INTRODUCTION: SARS-CoV-2 infections can result in a broad spectrum of symptoms from mild to life-threatening. Long-term consequences on lung function are not well understood yet. METHODS: In our study, we have examined 134 post-COVID patients (aged 54.83 ± 14.4 years) with dyspnea on exertion as a leading symptom 6 weeks to 24 months after a SARS-CoV-2 infection for bronchodilator responsiveness during their stay in our pulmonary rehabilitation clinic. RESULTS: Prior to bronchial dilation, 6 out of 134 patients (4.47%) presented an FEV1/FVC ratio below lower limit of normal (Z-score = -1.645) indicative of an obstructive airway disease. Following inhalation of a

  • Krooss, S. A.
  • Klefenz, I.
  • Ott, M.
  • Klawonn, F.
  • Leitl, D.
  • Schneeberger, T.
  • Jarosch, I.
  • Vogelmeier, C. F.
  • Lommatzsch, M.
  • Gloeckl, R.
  • Koczulla, A. R.

Keywords

  • Humans
  • *COVID-19/complications
  • Middle Aged
  • Male
  • Female
  • *Bronchodilator Agents/therapeutic use
  • Aged
  • *SARS-CoV-2
  • Forced Expiratory Volume
  • Adult
  • Dyspnea/etiology
  • Adrenergic beta-2 Receptor Agonists/therapeutic use
  • Airway inflammation
  • Bronchodilator responsiveness
  • Post-COVID
  • Viral infection
Publication details
DOI: 10.1159/000540297
Journal: Respiration
Pages: 622-629 
Number: 10
Work Type: Original
Location: BREATH, UGMLC
Disease Area: PALI
Partner / Member: JLU, MHH, UMR
Access-Number: 39008969

DZL Engagements

chevron-down